gene_id,gene_symbol,name,in_manning,in_kinmap,in_uniprot_kinasedomain,in_IDG_darkkinases,n_pubmed_citations_2013to2018,pharos_designation,PDB,title,expMethod,deposition_date,last_modification_date,resolution,InChI,InChIKey,chemicalName,smiles,formula,molecularWeight
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,3P1A,Structure of human Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1),X-RAY DIFFRACTION,2010-09-30,2011-07-13,1.7,"InChI=1S/C2H6OS/c1-4(2)3/h1-2H3;InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2",IAZDPXIOMUYVGZ-UHFFFAOYSA-N;LYCAIKOWRPUZTN-UHFFFAOYSA-N,"DIMETHYL SULFOXIDE;1,2-ETHANEDIOL",CS(=O)C;C(CO)O,C2 H6 O S;C2 H6 O2,78.133;62.068
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VD1,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA-848125,X-RAY DIFFRACTION,2017-04-01,2017-10-11,1.7,"InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29);InChI=1S/C4H10O3/c5-1-3-7-4-2-6/h5-6H,1-4H2",RXZMYLDMFYNEIM-UHFFFAOYSA-N;MTHSVFCYNBDYFN-UHFFFAOYSA-N,"N,1,4,4-TETRAMETHYL-8-{[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H]QUINAZOLINE-3-CARBOXAMIDE;DI(HYDROXYETHYL)ETHER",CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C;C(COCCO)O,C25 H32 N8 O;C4 H10 O3,460.575;106.12
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VD0,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775,X-RAY DIFFRACTION,2017-04-01,2017-10-11,2.13,"InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31);InChI=1S/C4H10O3/c5-1-3-7-4-2-6/h5-6H,1-4H2",BKWJAKQVGHWELA-UHFFFAOYSA-N;MTHSVFCYNBDYFN-UHFFFAOYSA-N,"1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one;DI(HYDROXYETHYL)ETHER",CC(C)(c1cccc(n1)N2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)C(=O)N2CC=C)O;C(COCCO)O,C27 H32 N8 O2;C4 H10 O3,500.595;106.12
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VD3,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (de-phosphorylated) IN COMPLEX WITH SARACATINIB,X-RAY DIFFRACTION,2017-04-01,2017-10-11,1.8,"InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2;InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31);InChI=1S/C4H10O3/c5-1-3-7-4-2-6/h5-6H,1-4H2",LYCAIKOWRPUZTN-UHFFFAOYSA-N;OUKYUETWWIPKQR-UHFFFAOYSA-N;MTHSVFCYNBDYFN-UHFFFAOYSA-N,"1,2-ETHANEDIOL;N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE;DI(HYDROXYETHYL)ETHER",C(CO)O;CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl;C(COCCO)O,C2 H6 O2;C27 H32 Cl N5 O5;C4 H10 O3,62.068;542.026;106.12
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VCX,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB,X-RAY DIFFRACTION,2017-04-01,2017-10-11,2.7,"InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2;InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)",LYCAIKOWRPUZTN-UHFFFAOYSA-N;OUKYUETWWIPKQR-UHFFFAOYSA-N,"1,2-ETHANEDIOL;N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE",C(CO)O;CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl,C2 H6 O2;C27 H32 Cl N5 O5,62.068;542.026
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VCY,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB,X-RAY DIFFRACTION,2017-04-01,2017-10-11,1.56,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31);InChI=1S/C2H6OS/c1-4(2)3/h1-2H3;InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2;InChI=1S/C4H10O3/c5-1-3-7-4-2-6/h5-6H,1-4H2",UBPYILGKFZZVDX-UHFFFAOYSA-N;IAZDPXIOMUYVGZ-UHFFFAOYSA-N;LYCAIKOWRPUZTN-UHFFFAOYSA-N;MTHSVFCYNBDYFN-UHFFFAOYSA-N,"4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;DIMETHYL SULFOXIDE;1,2-ETHANEDIOL;DI(HYDROXYETHYL)ETHER",CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC;CS(=O)C;C(CO)O;C(COCCO)O,C26 H29 Cl2 N5 O3;C2 H6 O S;C2 H6 O2;C4 H10 O3,530.446;78.133;62.068;106.12
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VCZ,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Bosutinib isomer,X-RAY DIFFRACTION,2017-04-01,2017-10-11,1.5,"InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2;InChI=1S/C4H10O3/c5-1-3-7-4-2-6/h5-6H,1-4H2;InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-24-14-22-19(13-23(24)34-2)25(17(15-29)16-30-22)31-18-11-20(27)26(35-3)21(28)12-18/h11-14,16H,4-10H2,1-3H3,(H,30,31)",LYCAIKOWRPUZTN-UHFFFAOYSA-N;MTHSVFCYNBDYFN-UHFFFAOYSA-N;YCLIWTLPTXAGPQ-UHFFFAOYSA-N,"1,2-ETHANEDIOL;DI(HYDROXYETHYL)ETHER;4-[(3,5-DICHLORO-4-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYLPIPERAZIN-1-YL)PROPOXY]QUINOLINE-3-CARBONITRILE",C(CO)O;C(COCCO)O;CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(c(c4)Cl)OC)Cl,C2 H6 O2;C4 H10 O3;C26 H29 Cl2 N5 O3,62.068;106.12;530.446
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VCV,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Dasatinib,X-RAY DIFFRACTION,2017-04-01,2017-10-11,1.92,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);InChI=1S/ClH/h1H/p-1;InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2;InChI=1S/C4H10NO6P/c1-2(3(5)4(6)7)11-12(8,9)10/h2-3H,5H2,1H3,(H,6,7)(H2,8,9,10)/t2-,3+/m1/s1",ZBNZXTGUTAYRHI-UHFFFAOYSA-N;VEXZGXHMUGYJMC-UHFFFAOYSA-M;LYCAIKOWRPUZTN-UHFFFAOYSA-N;USRGIUJOYOXOQJ-GBXIJSLDSA-N,"N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE;CHLORIDE ION;1,2-ETHANEDIOL;PHOSPHOTHREONINE",Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl;[Cl-];C(CO)O;C[C@H]([C@@H](C(=O)O)N)OP(=O)(O)O,C22 H26 Cl N7 O2 S;Cl -1;C2 H6 O2;C4 H10 N O6 P,488.006;35.453;62.068;199.099
9088,PKMYT1,"protein kinase, membrane associated tyrosine/threonine 1",1,1,1,1,21,Tchem,5VCW,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Pelitinib,X-RAY DIFFRACTION,2017-04-01,2017-10-11,2.25,"InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+;InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2;InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2",WVUNYSQLFKLYNI-AATRIKPKSA-N;LYCAIKOWRPUZTN-UHFFFAOYSA-N;QAOWNCQODCNURD-UHFFFAOYSA-L,"(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide;1,2-ETHANEDIOL;SULFATE ION",CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F;C(CO)O;[O-]S(=O)(=O)[O-],C24 H23 Cl F N5 O2;C2 H6 O2;O4 S -2,467.923;62.068;96.063
